Brentuximab is a type of monoclonal antibody (MA). MAs target particular proteins on the cancer cells surface. Brentuximab targets a protein called CD 30, it sticks to the CD30 protein and delivers a drug to the cell. The drug then kills the cell. Early trials suggest that patients may find treatment with brentuximab easier to tolerate.
Brentuximab vedotin (Adcetris) for treatment naive Hodgkin’s Lymphoma
Interventions:
Adriamycin
, Brentuximab vedotin (Adcetris; SGN-35)
, Dacarbazine (dacarbazine citrate)
, Vinblastine (vinblastine sulfate)
Indications:
Hodgkin lymphoma
Therapeutic Areas:
Haematological Cancer and Lymphomas
Year:
2017